Holen Sie sich die Stockscreener-App
416.23
3.12%
-13.79
Schlusskurs vom Vortag:
$430.02
Offen:
$430.45
24-Stunden-Volumen:
594.68K
Relative Volume:
0.54
Marktkapitalisierung:
$55.02B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,730.69
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
-10.39%
1M Leistung:
-5.89%
6M Leistung:
+37.04%
1J Leistung:
+62.81%
1-Tages-Spanne:
$415.48
$433.31
1-Wochen-Bereich:
$415.48
$479.79
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
416.44 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.17 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.53 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
891.12 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiples2025 Market Sentiment & Community Driven Trade Alerts - Newser
Do Alnylam Pharmaceuticals’ (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? - Yahoo Finance
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
1832 Asset Management L.P. Raises Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam announces board changes, appoints Stuart Arbuckle as director By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals Announces Changes to Board of Directors - PharmiWeb.com
Alnylam Pharmaceuticals announces changes to board of directors - marketscreener.com
Alnylam announces board changes, appoints Stuart Arbuckle as director - Investing.com
Panagora Asset Management Inc. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Quadrature Capital Ltd Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. (DUL) stock boost dividends furtherJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Will Alnylam Pharmaceuticals Inc. (DUL) stock benefit from mergersTrend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharma, Atour Lifestyle, MongoDB Among These 10 Stocks Worth Watching - Investor's Business Daily
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M - Benzinga
West Family Investments Inc. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Hsbc Holdings PLC Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock good for wealth creationJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing - Barron's
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value - Yahoo Finance
2,032,680 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Norges Bank - MarketBeat
Advisors Asset Management Inc. Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Loomis Sayles & Co. L P Sells 10,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Korea Investment CORP Acquires 5,096 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
State Board of Administration of Florida Retirement System Increases Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):